small molecule

NULIBRY

FOSDENOPTERIN HYDROBROMIDE

Loss of exclusivityApril 2029latest FDA-listed patent expiry

CompanySentynl Therapeutics, Inc. →View the full company profile on CliffBio

Drug detail

Brand name	NULIBRY
Active ingredient	FOSDENOPTERIN HYDROBROMIDE
Strength	EQ 9.5MG BASE/VIAL
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	February 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
7504095	April 2029	product

Regulatory exclusivity

Code	Expires
ODE-342	February 2028
NCE	February 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Sentynl Therapeutics, Inc.